 Welcome back, folks. This is Jacob Schrupp, filling in for Tom O'Brien. We were actually joined today by Elliott Wellenbach, the Senior Vice President over at Direction and Institutional ETF Sales and Capital Markets Strategist. Elliott, how are you doing? Good, Jacob. I'm excited to be here. Thanks for having me. Fantastic. You know, there's quite a bit going on, actually. I want to start off first. Just kind of looking at what you got over here at DPST. This is the daily regional banks bull three-time shares. Now, of course, we had a lot of stuff come out with earnings, of course, the bank corp and Citibank. It was curious if you can give us a little insight in, you know, this is the three times leveraged bull ETF. You know, it's funny, before we even begin, I want to say it's been funny. Years ago, I had traded in Gush in Drip and I was a young guy and, you know, trying to learn and get my footing and I really found that using these were just really changed kind of my strategies, which I thought was really impressive. Yeah, no, definitely. Yes, most of our products are leverage and inverse, short-term tactical trading tools, very powerful, you know, very important to monitor. But yeah, no, as you mentioned, regional banks, I mean, the financials, you know, kind of kick off Q1 earnings. They did last week and, you know, really Q1 earnings season has continued this week. The regional banks, about 40% of that basket is reporting this week. And as you mentioned, DPST is our triple leveraged ETF off of the regional banks select sector. You know, we've seen kind of, you know, mixed earnings coming out of the regional banks. The NII, you know, the net interest income is definitely something that has been watched with higher rates, especially with the regional banks being, you know, a little bit more sensitive to higher rates in their core business as opposed to, you know, some of the, you know, larger, you know, banks and financials that have, you know, broader, you know, areas of their business that they can rely on where the regional banks really, you know, are impacted by that NII. So it's been, it's definitely been interesting. And, you know, even in the broader financials that you mentioned, you know, we've seen Goldman City, JP Morgan, Wells Fargo, Bank of America, they've already all reported. And those are all part of the financial select sector. So those are the, you know, the larger financial banks and financial companies within the US as opposed to the regionals that are going to be your smaller regional players. But that basket as well, we have a triple leveraged ETF off of that, the financial select sector, FAS, and a triple inverse as well, FAC. And that basket is already reported as well, 40% so far, starting off Friday of last week and then through this week. And we didn't even see seeing, you know, the higher rate environment impacting, you know, their net interest income, even when they have, you know, businesses that, you know, can help support, you know, their broader business when, you know, instead of just, you know, looking at, you know, loans, and, you know, also just, you know, that interest that they're, they have to pay back to, you know, people holding money with them. Yeah, and taking a look too at the financial bull and bear, again, that's FAS and FAZ. But you can see here too, obviously the top 10 holdings, you got Berkshire, JP Morgan, Visa, Mastercard, Bank, and so on. And then you have these index sector weightings as well. And this will, you know, this is the case for all the leveraged shares, leveraged ETFs that direction provides as well. And so I had a pretty good time sitting here and looking through a lot of these before the show as well. You know, into that as well, we had United Health Care, of course, report earnings as well. They did all right. And you guys have an health care bull three times leveraged as well. I mean, what's the major composite of that? That's Lily, United Health Group, Johnson & Johnson. Of course, Lily coming out with some interesting news too, with Zep bound being effective actually for sleep apnea too. So if you can tell us a little bit about cure and what we're looking at with that? Yeah, no, definitely. That's another, you know, larger percentage of the health care select sector are, you know, triple leveraged ETF cure that is off of that. You know, it's been a little bit mixed for the health care sector, approximately 20% of that basket is reported so far this week. You know, we saw Abbott, you know, that's part of that index big beat razor annual profit forecast. And as you mentioned, Eli Lilly, they're not reporting for another week and a half. So that's that's the largest holding within cure and in that sector. And it's going to be pretty interesting. You know, a lot has been going on the past year with, you know, the weight loss drugs, you know, the demand for that. And it's going to be interesting to see how sales and growth in that space for not only Eli Lilly, but, you know, a handful of those, you know, large health care names in that sector, how that's going to impact their earnings. Because there's been a lot of, you know, kind of hype around that. And also, you know, demand from the consumer as well. Absolutely. And, you know, at the price that Eli Lilly trades at right now, you know, we're at 749 a share. This is a great way, especially with cure, to get exposure to, I mean, listen, Eli Lilly, I think is poised fantastically, right? Zep bound is even going through a supply kind of choke right now, which is only going to drive up the cost for it. And a lot of times I, you know, something like 749 a share for Eli Lilly is a little bit prohibitive for a lot of people. And so to get exposure to that stock and something like this, you know, I think is fantastic as well. That's what I find so neat with a lot of these leverage ETFs. Yep. Great way to trade around earnings, short term, you know, as you mentioned, you know, if you're looking for concentrated exposure, but don't want to be trading that, you know, just that individual name, you know, it's a great way to get a basket, you know, through a leverage ETF there for short term trading. And, you know, one of the big things, of course, you know, Tom O'Brien, he, you know, runs his newsletter and everything. We've been looking at gold a lot, right? And direction has, of course, nugget, which is a three times long, and then dust as well. And so I'm kind of curious what you guys are looking at with that. Obviously, gold has had this kind of, you know, I would say in recent times, meteoric rise, which has been fantastic for all gold holders. And, you know, nugget has returned pretty fantastically for that whole run. Let's take a look at the chart here as well. And this is on a one year. I mean, we're trading up 38, 28 right now, up 2.9% for the day. And I mean, seriously, look, right? This is May 1st, you know, excuse me, March 1st of the beginning of this year. And then we've just seen it really, really kind of follow gold on the way up as well. Yeah, yeah, no, definitely. Gold has been kind of, you know, earlier this year hitting all-time highs. And, you know, another thing that has really impacted as of recent is kind of some geopolitical conflict going on in the Middle East right now, kind of that flight to safety trade, especially in the gold. And as you mentioned, we have leveraged gold miner ETFs. So not the actual physical gold, but the gold mining equities, nugget and dust are 2x in the gold miners. And then we do have our junior gold miner 2x as well, JNUG, JNUG, and JPST, the inverse there. So, no, definitely, you know, we've seen gold or the gold miners lag gold just a little bit. Definitely. But with, you know, the spot price going up, and usually they follow really closely behind. So, Elliott, thank you so much for joining us. This has been fantastic. And we're looking forward to hearing from you soon. Yeah, Jacob. Thank you for having me. Fantastic. Take care now. Folks, stay tuned. We'll be right back.